CSTL Earnings

CSTL reported its FY2025Q3 earnings on 2025-11-03, showcasing a revenue of 83.00M against an estimate of 71.00M, resulting in a 16.74% surprise. The EPS was -0.02, surpassing the expected -0.34 by 94.12% . The stock experienced a 21.7% price change on the earnings day and a 27.13% change over the next five days, reflecting market reactions to the results.

Following CSTL's FY2025Q3 earnings announcement on 2025-11-03, the stock price moved by 21.70% on the day of the release. Over the subsequent five days, it saw a 27.13% change. Historically, CSTL's stock price tends to shift by an average of -3.65% in the 10 days leading up to earnings and +4.86% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CSTL’s annual revenue to reach 76.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 4.91% and EPS estimates Revise Upward by 5.53% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CSTL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 4.91%, while EPS estimates moved Revise Upward by 5.53% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CSTL's stock price typically moves by -3.65% in the 10 days before its earnings and +4.86% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 76.00M.

The earnings call presents mixed signals: positive revenue growth and pipeline developments are countered by declining margins, increased expenses, and a net loss. The raised revenue guidance is a positive sign, but the lack of clarity on reimbursement pathways and flat SCC volumes temper enthusiasm. The Q&A reveals some analyst concerns, particularly regarding reimbursement and FDA approval impacts. The absence of a market cap limits prediction accuracy, but the overall sentiment leans towards neutral, given the balancing of positive growth prospects against financial pressures and uncertainties.